A new review considers how SGLT2 inhibitors like dapagliflozin and empagliflozin have been shown to clinically improve gout while reducing its cardiometabolic and renal comorbidities.
An analysis of more than 20,000 people with type 2 diabetes suggests initiating therapy with an SGLT2 inhibitor, as a second-line treatment to metformin, was associated with a lower risk of developing gout relative to other second-line therapies.
An analysis of 100 week data from the KEEPsAKE 1 and 2 trials presented at EULAR 2023 offers insight into the long-term effects of risankizumab use in people with psoriatic arthritis.